<DOC>
	<DOCNO>NCT01285401</DOCNO>
	<brief_summary>The drug test call VigantOL® oil - effective form Vitamin D hormone supplement ( cholecalciferol ) . Low level Vitamin D describe associate high risk develop Multiple Sclerosis ( MS ) , know 90 % patient Multiple Sclerosis Vitamin D deficiency . Rebif® known effective treatment slow progression MS . The purpose research trial evaluate VigantOL® oil top Rebif® benefit progression MS compare Rebif® placebo . Disease activity assess clinical examination Magnetic Resonance Imaging ( MRI ) . The planned study treatment duration study participant 48 week , study consist total 8 visit . Study participant already pass Week 48 time approval Protocol Amendment 5 study duration 96 week total 12 visit . During study , participant undergo physical examination , neurological assessment , safety assessment , blood test urinalysis ( include pregnancy test ) .</brief_summary>
	<brief_title>Supplementation VigantOL® Oil Versus Placebo Add-on Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosis relapsingremitting form MS Brain and/or spinal MRI finding typical MS A first clinical event prior Screening . Disease activity Expanded Disability Status Scale ( EDSS ) score less , equal 4.0 Screening . Currently treat interferonbeta1a 44mg ( tiw ) sc Willingness ability comply protocol Written inform consent Pregnancy lactation period Any disease MS could better explain sign symptom . Complete transverse myelitis bilateral optic neuritis . Currently receive use time monoclonal antibody , mitoxantrone , cytotoxic immunosuppressive therapy ( exclude systemic steroid adrenocorticotrophic hormone [ ACTH ] ) , B cell modulate therapy ( e.g . RituxiMab BelimuMab ) , total lymphoid irradiation bone marrow transplantation . Use cytokine interferon anticytokine therapy , intravenous immunoglobulin , plasmapheresis , investigational drug experimental procedure Use oral systemic corticosteroid ACTH Have abnormality Vitamin D relate hormonal system low dietary intake decrease sun exposure , i.e . primary hyperparathyroidism granulomatous disorder . Have urine calcium/creatinine ( mmol/mmol ) ratio great 1.0 hypercalcaemia Are take medication influence Vitamin D metabolism corticosteroid , e.g. , phenytoin , barbiturate , thiazide diuretic cardiac glycoside . Are take 1000 IU ( 25 µg ) Vitamin D supplement daily . Have condition increase susceptibility hypercalcaemia , e.g. , know arrhythmia heart disease , treatment Digitalis , Hydrochlorothiazide suffer nephrolithiasis . Have inadequate liver function Moderate severe renal impairment Inadequate bone marrow reserve History presence serious acute heart disease uncontrolled cardiac dysrhythmia arrhythmia , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure ( NYHA class 3 4 ) . History presence severe depression , history suicide attempt , current suicidal ideation . Epilepsy seizures adequately control treatment . Current past alcohol drug abuse . Any major medical psychiatric illness ( psychosis , bipolar disorder ) opinion Investigator could create undue risk subject could affect adherence trial protocol . Known contraindication treatment vitamin D Known hypersensitivity interferon excipient ( ) Known hypersensitivity gadolinium . Any condition would prevent subject undergoing MRI scan . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) . Positive HIV , hepatitis C , hepatitis B ( HBsAg HBc antibody ) serology ( test perform screening ) . Legal incapacity limit legal capacity . Another current autoimmune disease , except diabetes . Have experience relapse within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Rebif</keyword>
	<keyword>VigantOL® oil</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Add-on treatment</keyword>
</DOC>